To determine the role of exenatide, let's analyze each option based on their mechanisms in pharmacology and physiology:
-
Glucagon like peptide 1 (GLP1) receptor agonist:
GLP-1 receptor agonists are a class of medications that mimic the action of the incretin hormone GLP-1. They improve blood glucose control by enhancing insulin secretion in a glucose-dependent manner, inhibiting glucagon release, delaying gastric emptying, and promoting satiety. Exenatide is indeed a GLP-1 receptor agonist.
-
Diphenyl Peptidase-4 (DPP4) inhibitors:
DPP-4 inhibitors are another class of glucose-lowering agents. They work by inhibiting the enzyme dipeptidyl peptidase-4, which results in prolonged action of incretin hormones. These hormones help increase insulin release in response to meals and decrease the release of stored glucose. Exenatide is not a DPP-4 inhibitor.
-
Facilitator of glucose transport across the cell:
Medications in this category, such as insulin mimetics or insulin itself, facilitate glucose uptake by tissues. This is not the mechanism of action for exenatide.
-
Inhibitor of glucose absorption in the GIT:
This refers to drugs like alpha-glucosidase inhibitors, which slow down carbohydrate absorption in the intestine. Exenatide does not work this way.
Therefore, based on the mechanism of action, the correct answer is:
Glucagon like peptide 1 (GLP1) receptor agonist
The initially provided correct answer (Diphenyl Peptidase-4 (DPP4) inhibitors) appears to be a mistake. Exenatide is categorized under GLP-1 receptor agonists, which aligns with its pharmacological properties.